$56.20 0.00 (%) Merck & Co Inc - NYSE

Oct. 29, 2014 | 04:00 PM

Partner Headlines

  1. Dividend Aristocrats In Focus Parts 30: Sigma-Aldrich

    GuruFocus | Oct. 28, 2014 | 15:17PM EST
  2. French Drugmaker Sanofi Warns Of Tougher Competition

    IBD | Oct. 28, 2014 | 14:42PM EST
  3. Video: Facebook, Gilead Post Earnings After The Close

    IBD | Oct. 28, 2014 | 14:00PM EST
  4. Fast Money Traders Discuss Merck, Garmin And Sarepta Therapeutics

    Benzinga | Oct. 27, 2014 | 20:18PM EST
  5. Merck sales fall, miss views

    IBD | Oct. 27, 2014 | 18:55PM EST
  6. Markets Virtually Flat, Oil Continues To Decline Following Bearish Outlook

    Benzinga | Oct. 27, 2014 | 16:58PM EST
  7. Gilead Rises Ahead Of Q3 Earnings As Rivals Wobble

    IBD | Oct. 27, 2014 | 15:38PM EST
  8. Merck Conference Call Highlights

    Benzinga | Oct. 27, 2014 | 15:34PM EST
  9. Mid-Afternoon Market Update: NQ Mobile Climbs On SEC Filing; Huntsman Shares Slide

    Benzinga | Oct. 27, 2014 | 15:15PM EST
  10. Mid-Day Market Update: Micron Gains On Buyback Announcement; Sarepta Shares Dip

    Benzinga | Oct. 27, 2014 | 12:41PM EST
  11. Mid-Morning Market Update: Markets Down; Merck Posts Upbeat Earnings

    Benzinga | Oct. 27, 2014 | 11:12AM EST
  12. Stock Futures Point Lower; Brazil Vote Hammers Petrobras

    IBD | Oct. 27, 2014 | 09:05AM EST
  13. #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line With Expectations

    Benzinga | Oct. 27, 2014 | 08:19AM EST
  14. US Stock Futures Down Ahead Of Economic Data

    Benzinga | Oct. 27, 2014 | 07:35AM EST
  15. Earnings Scheduled For October 27, 2014

    Benzinga | Oct. 27, 2014 | 05:06AM EST
  16. Keep an Eye on These 7 Stocks for October 27, 2014

    Benzinga | Oct. 27, 2014 | 04:21AM EST
  17. Earnings Expectations For The Week Of October 27: Facebook, Exxon, Pfizer And Much More

    Benzinga | Oct. 26, 2014 | 16:55PM EST
  18. Stocks Put End To Four-Week Slide

    IBD | Oct. 24, 2014 | 16:56PM EST
  19. Fast Money Halftime Report Final Trade From October 24

    Benzinga | Oct. 24, 2014 | 16:50PM EST
  20. Bristol-Myers Beats Q3 Views As Eliquis Revives

    IBD | Oct. 24, 2014 | 13:23PM EST
  21. Fast Money Picks For October 23

    Benzinga | Oct. 23, 2014 | 07:00AM EST
  22. Drug ETFs Attractive Buys On Pullback

    Benzinga | Oct. 22, 2014 | 17:10PM EST
  23. Gilead's Hep C Dream Drug Faces Demanding Investors

    IBD | Oct. 22, 2014 | 16:44PM EST
  24. What is Abner Herrman Investing In?

    GuruFocus | Oct. 16, 2014 | 15:59PM EST
  25. Will Activis Win Competition For Allergan's Affection?

    Benzinga | Oct. 16, 2014 | 11:10AM EST
  26. IPO Calendar: Biotech Companies Lead List Of 7 IPOs

    IBD | Oct. 13, 2014 | 16:33PM EST
  27. Alnylam Drug Scores Against Rare Nerve Disease

    IBD | Oct. 13, 2014 | 13:59PM EST
  28. Merck to release hep C data

    IBD | Oct. 8, 2014 | 18:38PM EST
  29. Merck, Bristol, Arrowhead Prep Hepatitis Studies

    IBD | Oct. 8, 2014 | 13:36PM EST
  30. Bristol-Myers Pulls FDA Filing For 2-Drug Hep C Combo

    IBD | Oct. 7, 2014 | 11:13AM EST
  31. 2 Mutual Funds Holding Hospital Stocks

    Benzinga | Oct. 6, 2014 | 10:38AM EST
  32. Will Gilead Sciences Score Healthy Gains For Investors?

    IBD | Oct. 2, 2014 | 13:03PM EST
  33. J&J Buying Alios, Going Up Against Gilead

    IBD | Sep. 30, 2014 | 12:02PM EST
  34. Merck & Co., Inc. Stock Still Holding Its Position As A Big-Pharma Leader

    Benzinga | Sep. 29, 2014 | 13:31PM EST
  35. Reasons Why I Will Bet on Sigma

    GuruFocus | Sep. 26, 2014 | 16:27PM EST
  36. Fast Money Halftime Report Final Trade From September 26 - Merck & Co., Inc., NCR Corporation And BP plc

    Benzinga | Sep. 26, 2014 | 14:26PM EST
  37. Gilead's New HIV Drug Key To Long-Term Strategy

    IBD | Sep. 24, 2014 | 17:29PM EST
  38. 5 Big Deals Lifting German M&A In U.S. To Record High

    IBD | Sep. 22, 2014 | 17:57PM EST
  39. Citigroup Inc, Hertz Global Holdings, Inc. Highlight Fast Money Halftime Report Final Trade From September 22

    Benzinga | Sep. 22, 2014 | 14:54PM EST
  40. Sigma-Aldrich Hits High On Sale To Germany's Merck

    IBD | Sep. 22, 2014 | 11:30AM EST
  41. Merck Presents First Phase 3 Data In Japanese Patients for Omarigliptin, An Investigational Once-Weekly DPP-4 Inhibitor For Type 2 Diabetes

    Benzinga | Sep. 17, 2014 | 09:34AM EST
  42. The Dogs of the Dow Lost Some Steam In The August Heat, But Maintained Their Lead

    GuruFocus | Sep. 16, 2014 | 16:58PM EST
  43. The Dogs of the Dow Lost Some Steam In The August Heat, But Maintained Their Lead

    GuruFocus | Sep. 16, 2014 | 15:16PM EST
  44. Is Merck & Co., Inc. A Leader In A Red Hot Market?

    Benzinga | Sep. 10, 2014 | 14:50PM EST
  45. Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. Over Skin Cancer Drug

    Benzinga | Sep. 5, 2014 | 16:04PM EST
  46. Merck PD-1 Inhibitor Approved For Skin Cancer

    IBD | Sep. 4, 2014 | 16:33PM EST
  47. 4 Biotechs That Might Be Bought Soon

    IBD | Aug. 29, 2014 | 11:53AM EST
  48. I Am Sure This Pharma-Company Suits Your Portfolio

    GuruFocus | Aug. 28, 2014 | 13:52PM EST
  49. Higher Yielding Stocks With A Cheap EV/EBITDA Ratio And Low Debt Figures

    GuruFocus | Aug. 28, 2014 | 12:21PM EST
  50. Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend

    Benzinga | Aug. 27, 2014 | 17:17PM EST
Trading Center